Failure To Comply With BPCIA Mandates Precludes A Declaratory Judgment Suit

Dec 2, 2014

Reading Time : 1 min

In a slip opinion, the Southern District of New York Court recognized that the BPCIA statutory framework governs the dispute resolution process for disputes relating to the manufacture and marketing of biosimilar products (e.g., biologic drugs which are “highly similar” to an already FDA approved “reference product”). While a reference product enjoys exclusivity for a period of twelve years, the BPCIA provides for a relatively quick and inexpensive methodology for biosimilar manufacturers to gain FDA approval for their drugs which have ‘“no clinically meaningful differences’” from the reference product. The BPCIA includes a dispute resolution mechanism that is designed to ensure that patent disputes are resolved before the reference product’s exclusivity period terminates. The dispute resolution process mandated by the BPCIA includes the exchange of information and various notices to the parties. The court noted that, even had it not already found that the matter involved no actual case or controversy, the failure to adhere to the dispute resolution process set forth in the BPCIA will preclude the manufacturer of a biosimilar product from seeking a declaratory judgment of patent invalidity against a reference product sponsor.

Celltrion Healthcare Co., Ltd. V. Kennedy Trust for Rheumatology Research, 2014 WL 6765996 (S.D.N.Y. Dec. 1, 2014).

Share This Insight

Categories

Previous Entries

IP Newsflash

February 24, 2026

The Southern District of Florida recently dismissed a complaint without prejudice because the allegations used a form of “shotgun pleading.” The court explained that a shotgun pleading includes those where every count incorporates every preceding paragraph into each cause of action, and that dismissal of such pleadings was required under Eleventh Circuit precedent.

...

Read More

IP Newsflash

February 20, 2026

The Federal Circuit recently addressed whether the PTO must conduct notice‑and‑comment rulemaking before issuing instructions that guide how the Board should exercise discretion at the institution stage of IPRs. The court held that no such rulemaking is required. Instructions to the Board regarding its use of the Director’s delegated discretionary authority not to institute review are merely general statements of policy exempt from notice-and-comment rulemaking.  

...

Read More

IP Newsflash

February 18, 2026

The District Court for the District of Delaware recently invalidated claims directed to a panoramic objective lens for lack of enablement, holding the claims impermissibly recited a single element in means‑plus‑function form. Under § 112, ¶ 6, “[a]n element in a claim for a combination may be expressed as a means or step for performing a specified function….” By its plain terms, the statute permits means‑plus‑function claiming only in the context of a “combination.” In other words, a claim may not consist solely of a single means‑plus‑function element. Claims drafted as a single means are invalid for lack of enablement as a matter of law.

...

Read More

IP Newsflash

February 13, 2026

In an ANDA litigation, the District of Delaware recently denied the defendants’ motion to compel the production of correspondence between the plaintiffs’ testifying expert and a third-party analyst who had performed experiments and provided data used by the testifying expert. The court found that the scope of material sought by the motion was overbroad and disproportionate to the needs of the case.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.